Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.

被引：7
|
作者：
Cheng, Ke
Lv, Wan-Rui
Li, Xiaofen
Tian, Bole
Cao, Dan
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16213
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wanrui
    Li, Xiaofen
    Chang, Chen
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16244 - E16244
  • [2] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Shui, Lin
    Cheng, Ke
    Li, Xiaofen
    Shui, Pixian
    Zhou, Xiaohan
    Li, Jian
    Yi, Cheng
    Cao, Dan
    BMC CANCER, 2020, 20 (01)
  • [3] Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
    Lin Shui
    Ke Cheng
    Xiaofen Li
    Pixian Shui
    Xiaohan Zhou
    Jian Li
    Cheng Yi
    Dan Cao
    BMC Cancer, 20
  • [4] Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
    Wei, M.
    Shi, S.
    Li, J.
    Du, N.
    Yu, X.
    Xu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S933 - S933
  • [5] Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
    Chang, Chen
    Li, Xiaofen
    Cao, Dan
    BMC CANCER, 2021, 21 (01)
  • [6] Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
    Chen Chang
    Xiaofen Li
    Dan Cao
    BMC Cancer, 21
  • [7] Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer
    Kokkali, S.
    Drizou, M.
    Tripodaki, E.
    Stefanou, D.
    Magou, E.
    Zylis, D.
    Kapiris, M.
    Nasi, D.
    Georganta, C.
    Ardavanis, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [9] Toripalimab combined with nab-paclitaxel/docetaxel as second-line treatment in patients with advanced gastric cancer: Preliminary results from a single-arm, open-label phase II trial
    Zhang, T.
    Yu, D.
    Wang, J.
    Liu, J.
    Ma, H.
    Lin, Z.
    Jin, M.
    Zhang, J.
    Zhao, L.
    Liu, H.
    Hu, J.
    Zhang, Q.
    ANNALS OF ONCOLOGY, 2021, 32 : S1057 - S1058
  • [10] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
12345